Preclinical studies suggest that some NRAS-mutant cutaneous melanomas may also exhibit sensitivity to RAF or MEK inhibition [14], whereas KRAS mutations have conferred only marginal sensitivity [15]. The gene discussed is MAP2K7; the disease is melanoma.